Clinical Trials

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03269669 2026-04-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT01661881 2026-04-08

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

23 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT06561347 2026-03-31

ZEBRA

55 enrolled

Waldenstrom Macroglobulinemia

NCT03623373 2026-03-30

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

13 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT04115631 2026-03-23

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

360 enrolled

Lymphoma, Mantle-Cell

NCT06504940 2026-02-27

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

69 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT03609593 2026-02-25

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

42 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03755804 2026-02-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

232 enrolled

Hodgkin Disease, Neoplasms

NCT06854003 2026-02-20

BRAZAN

60 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT04624906 2026-02-04

BRAWM

63 enrolled

Waldenstrom Macroglobulinemia

NCT05508867 2026-01-20

MK-4280A-008

203 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

150 enrolled

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07259122 2025-12-02

ZBR in WM

43 enrolled

Waldenstrom Macroglobulinemia

NCT07208981 2025-10-06

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

169 enrolled

Phase 2 Not yet recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07206264 2025-10-03

ADAPT-MCL

45 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

20 enrolled

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT03834688 2025-08-11

PrE0405

33 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT03872180 2025-08-06

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

23 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Other hematologic neoplasm

69 enrolled 12 charts

Leukemia, Hairy Cell, Neoplasm, Residual

NCT04515238 2025-06-10

CLL2-BZAG

42 enrolled

Phase 2 Not yet recruiting

Leukemia, B-Cell

NCT07003464 2025-06-04

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04217317 2025-05-02

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT02224729 2025-04-30

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

24 enrolled 13 charts

Plasma cell

Multiple Myeloma

NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

23 enrolled

Lymphoma, Follicular

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL